Neuroleptic-induced catatonia after abrupt withdrawal of amantadine during neuroleptic therapy.
Catatonic reactions to high-potency neuroleptic drugs have been described in the literature. Our patient developed neuroleptic-induced catatonia (NIC) after abrupt withdrawal of amantadine, a dopaminergic agent that has been implicated in neuroleptic malignant syndrome (NMS) on its discontinuation. This case report adds support to the hypothesis that NIC and NMS are 2 syndromes on a continuum of dopamine blockade, each of which may be treated with or uncovered by amantadine therapy.
D000293:Adolescent; D000547:Amantadine / Q000009:adverse effects* / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy; D002389:Catatonia / Q000139:chemically induced*; D005260:Female; D006801:Humans; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D013375:Substance Withdrawal Syndrome; D013888:Thiothixene / Q000009:adverse effects
D014150:Antipsychotic Agents; D013888:Thiothixene; D000547:Amantadine